The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. It
is composed of extracellular domains, including a ligand-binding domain, a hydrophobic …

The development of epidermal growth factor receptor (EGFR) inhibitors was greeted with
tremendous enthusiasm in the therapy of squamous cell carcinoma of the head and neck …

Purpose To evaluate efficacy and toxicity of cetuximab plus carboplatin in recurrent or
metastatic nasopharyngeal carcinoma (NPC) resistant to platinum treatment. Patients and …

Novel therapeutic agents that target the epidermal growth factor receptor (EGFR) constitute
an important addition to the therapeutic armamentarium for the treatment of metastatic …

Head and neck cancer represents $5% of all cancers and> 500000 new cases are
diagnosed worldwide each year. Approximately 60–65% of patients with head and neck …

Squamous cell head and neck cancer (SCCHN) is the seventh most common cause of
cancer death worldwide and its incidence is rising rapidly in developing countries. Despite …

Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer
in the world. At present several therapeutic approaches, including surgical removal …

Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in
1986, numerous molecules have been targeted using therapeutic antibody technology …

Monoclonal antibodies targeting EGFR and VEGF represent exciting therapeutic strategies
that should be further evaluated both in combination with drugs acting on the same target at …

Chemotherapy is the standard approach to the treatment of patients with recurrent and
metastatic squamous cell carcinoma of the head and neck (SCCHN) and is also now a …